Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $905,627.80 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total value of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total value of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $335,091.68.

Natera Trading Down 0.2%

Shares of NASDAQ NTRA traded down $0.61 during trading hours on Wednesday, reaching $274.58. The stock had a trading volume of 1,128,660 shares, compared to its average volume of 1,104,859. The firm has a market cap of $39.32 billion, a price-to-earnings ratio of -168.45 and a beta of 1.51. Natera, Inc. has a fifty-two week low of $135.75 and a fifty-two week high of $288.04. The firm has a 50-day moving average of $251.03 and a 200-day moving average of $222.85.

Hedge Funds Weigh In On Natera

Several institutional investors have recently bought and sold shares of the company. Elevation Wealth Partners LLC purchased a new position in Natera during the 2nd quarter worth $30,000. Reflection Asset Management acquired a new stake in shares of Natera in the 4th quarter worth $29,000. Palladiem LLC purchased a new stake in shares of Natera in the fourth quarter valued at about $31,000. Bank of Jackson Hole Trust increased its stake in shares of Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares during the period. Finally, International Assets Investment Management LLC increased its stake in shares of Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. Morgan Stanley increased their price target on shares of Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. The Goldman Sachs Group started coverage on shares of Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective on the stock. William Blair initiated coverage on shares of Natera in a report on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, Barclays decreased their target price on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.